Try our Advanced Search for more refined results

Federal Trade Commission et al v. Actavis, Inc.

  1. May 09, 2014

    Generics Cos. Denied Quick Appeal In AndroGel Row With FTC

    A Georgia federal judge refused Friday to allow Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. to appeal a court's refusal to dismiss the Federal Trade Commission's pay-for-delay antitrust claims under the Noerr-Pennington doctrine, even though a federal court approved the underlying AndroGel patent settlement.

  2. April 23, 2014

    Generic Cos. Seek To Appeal Androgel Dismissal Denial

    Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. on Tuesday moved to immediately appeal a ruling that they were not immune from the Federal Trade Commission's pay-for-delay antitrust claims under the Noerr-Pennington doctrine, even though a federal court signed off on the underlying patent settlement.

  3. April 21, 2014

    Generic Cos. Again Lose Bid To Shake AndroGel Suit

    A Georgia federal judge on Monday rejected a renewed bid by Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. to nix the Federal Trade Commission's pay-for-delay case against them, finding that their patent settlement over testosterone replacement treatment Androgel is not entitled to Noerr-Pennington antitrust immunity.

  4. March 04, 2014

    Generic Drug Cos. Push To Ax FTC Pay-For-Delay Suit

    Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. urged a Georgia federal judge on Monday to nix the Federal Trade Commission's pay-for-delay case against them, saying their patent settlement was protected under Noerr-Pennington antitrust immunity.

  5. January 17, 2014

    Drug Cos. Say Noerr Doctrine Bars FTC's Pay-For-Delay Suit

    Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. once again moved to dismiss the Federal Trade Commission's pay-for-delay case against them Wednesday, arguing they were protected from the government's antitrust claims because a federal court had approved the underlying patent settlement.

  6. December 12, 2013

    Drugmakers Lose Bid For 'Indefinite' Extension In FTC Case

    The Federal Trade Commission's pay-for-delay case against Actavis Inc. and other drugmakers is now set to resume nearly six months after the U.S. Supreme Court revived the suit, with a Georgia judge on Tuesday giving the defendants 21 days to respond to the watchdog's complaint.

  7. April 09, 2009

    FTC Loses Venue Fight In Reverse Payment Deal Suit

    A judge has transferred the Federal Trade Commission's ongoing battle against reverse payment settlements out of a California federal court — a significant loss for the agency in a heated venue dispute with a group of pharmaceutical companies in the case.